Evaluation of a non-steroidal peripherally selective androgen receptor antagonist: oral bicalutamide in female pattern hair loss

This study titled Evaluation of a Non Steroidal Peripherally Selective Androgen Receptor Antagonist Oral Bicalutamide in Female Pattern Hair Loss aims to assess the efficacy of oral bicalutamide alone and in combination with topical minoxidil in improving hair growth among female patients aged 20 to 50 years diagnosed with FPHL Existing treatments such as minoxidil and oral antiandrogens have variable outcomes and notable side effects highlighting the need for safer more effective alternatives The study will be conducted over 18 months and will include 84 participants divided into three groups bicalutamide alone minoxidil alone and combination therapy Baseline and follow-up assessments will be done at 8 12 and 20 weeks including clinical photography trichoscopy hair density measurement and patient satisfaction scoring using standardized scales Sinclair Ludwig and Patient Global Assessment By comparing changes in hair density grading scores and patient reported outcomes the study seeks to establish the therapeutic potential and safety of oral bicalutamide as a novel treatment option for female pattern hair loss